Larvol Delta - Alpha-Cancer-Technologies-ACT-Publishes-PreClinical-Study-Results-in-Cancer-Cell-International-Demonstrating-Excellent-Safety-and-Signicant-AntiTumor-Activity-from-the-Companys-Next-Generation-ADC-ACT903

ACT-903 - Alpha Cancer Technologies

recombinant alpha-fetoprotein (ACT-101) - Alpha Cancer Technologies

https://www.businesswire.com/news/home/20230406005566/en/Alpha-Cancer-Technologies-ACT-Publishes-Pre-Clinical-Study-Results-in-Cancer-Cell-International-Demonstrating-Excellent-Safety-and-Significant-Anti-Tumor-Activity-from-the-Company%E2%80%99s-Next-Generation-ADC-ACT-903

Apr 6, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next